MolecuLight Inc. Florida Ontario

is a privately owned medical imaging company with global presence that offers fully commercialized point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging platform technology. MolecuLight's suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging and digital wounds measurement systems and their accessories, have scientifically proven capabilities that enhance wound care practices and outcomes across all places of service. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform "fluorescence imaging for bacterial presence location, and load" and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. 

Laura Jones-Donaldson, MolecuLight Inc., ljones@moleculight.com, T. +1.416.542.5507, www.moleculight.com

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-clinical-research-featured-at-the-upcoming-sawc-spring-2024-conference-302144511.html